9309-054 
9309-055 
9309-056 
9309-057 
9309-058 
9312-059 3 
9312-060 
9312-061 
9312-062 3 
9312-063 
9312-064 
Attachnait Et - F&ge 7 
(T) O’Shaughncssy, Joyce; National Institutes of Health, Bethesda, Maryland; Retroviral Mediated Transfer of 
the Human Multi-Drug Resistance Gene (MDR-1) into Hematopoietic Stem Cells During Autologous 
Transplantation after Intensive Chemotherapy for Breast Cancer. 
RAC Approval: 9-9-93/NTH Approval: 10-7-93 
(T) Kun, Larry E.; Sanford, R. A.; Brenner, Malcolm K.; and Heideman, Richard L.; St. Jude Childrens 
Research Hospital, Memphis, Tennessee; and Oldfield, Edward H.; National Institutes of Health, 
Bethesda, Maryland; Gene Therapy for Recurrent Pediatric Brain Tumors. 
RAC Approval: 9-9-93/NIH Approval: 10-7-93 
(T) Das Gupta, Tapas K. and Cohen, Edward P.; University of Illinois at Chicago; Chicago, Illinois; 
Immunization of Malignant Melanoma Patients with Interleukin 2-Secreting Melanoma Cells Expressing 
Defined Allogeneic Histocompatibility Antigens. 
RAC Approval: 9-10-93/NIH Approval: 4-19-94 
(T) Wong-Staal. Flossie: Poeschla. Eric: and Looney. David; University of California, San Diego. California: A 
Phase I Clinical Trial to Evaluate the Safety and Effects in HIV-1 Infected Humans of Autologous 
Lymphocytes Transduced with a Ribozvme that Cleaves HIV-1 RNA. 
RAC Approval: 9-10-93/NIH Approval: Pending 
(T) Economou, James S. and Glasby, John A.; University of California Medical Center, Los Angeles, 
California; Genetically Engineered Autologous Tumor Vaccines Producing Interleukin-2 for the Treatment of 
Metastatic Melanoma. 
RAC Approval: 9-10-93/NIH Approval: 12-2-93 
(T) Oldfield, Edward H. and Ram, Zvi; NIH, Bethesda, Maryland; Intrathecal Gene Therapy for the Treatment ' 
of Leptomeningeal Carcinomatosis. 
RAC Approval: 12-2-93/NIH Approval: 1-20-94 
Minor Modification: 7-5-94 
(T) Sobol. Robert E. and Rovston. Ivor: San Diego Regional Cancer Center. San Diego. California; Injection 
of Colon Carcinoma Patients with Autologous Irradiated Tumor Cells and Fibroblasts Genetically Modified to 
Secrete Interleukin-2. 
RAC Approval: 12-2-93/NIH Approval: Pending J 
(T) Schuening. Friedrich: Fred Hutchinson Cancer Research Center. Seattle. Washington; Retrovirus-Mediated 
Transfer of the cDNA for Human Glucocerebrosidase into Peripheral Blood Repopulating Cells of Patients 
with Gaucher’s Disease. 
RAC Approval: 12-2-93/NIH Approval: Pending il 
(T) Haubrich, Richard; University of California at San Diego Treatment Center, San Diego, California, and 
Merchant, Bruce; Viagene, Inc., San Diego, California; An Open Label, Phase 1/11 Clinical Trial to 
Evaluate the Safety and Biological Activity of HIV-rT(V) ( HIV-1 IIBenv /Retroviral Vector) in HIV-1 Infected 
Subjects. 
RAC Approval: 12-3-93/NIH Approval: 4-19-94 
Minor Modification: 7-11-94 
(T) Sznol, Mario; National Institutes of Health, Frederick, Maryland; A Phase I Trial of B7-Transfected 
Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell Mediated Immunity Against Tumor- 
Associated Antigens Presented by HLA-A2 or HLA-A1 in Patients with Stage TV Melanoma. 
RAC Approval: 12-3-93/NIH Approval: 4-19-94 
(T) Rubin, Joseph; Mayo Clinic, Rochester, Minnesota; Phase I Study of Immunotherapy of Advanced II 
Colorectal Carcinoma by Direct Gene Transfer into Hepatic Metastases. 
RAC Approval: 12-3-93/NIH Approval: 4-19-94 
[ 98 ] 
Recombinant DNA Research, Volume 20 
